---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-140078"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:49:30.230505+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phathom Q1 net loss $37.8M, on track to resubmit Erosive GERD NDA this quarter

## Summary
- Net loss $37.8M vs $40.7M YoY; operating expenses 36% lower than prior quarter due to cost controls after launch delay.
- Cash $129.6M at Mar 31, 2023; additional $100M term loan available, $175M upon FDA approval of VOQUEZNA for Erosive GERD.
- On track to resubmit Erosive GERD NDA this quarter; potential FDA approval and U.S. launch for Erosive GERD and H. pylori in Q4 2023.
- Ph3 PHALCON-NERD-301 trial met primary endpoint; regulatory submission for Non-Erosive GERD expected H2 2023.
- Coverage secured for 60% of commercial lives for VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori.

## SEC filing metadata
- accession: 0001193125-23-140078
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/0001193125-23-140078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/d457235d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-140078
- JSON: https://secwatch.observer/filing/0001193125-23-140078.json
- Plain text: https://secwatch.observer/filing/0001193125-23-140078.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income $37.8 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $37.8 million
  - Result: reported results
  source text: Net loss for the first quarter ended March 31, 2023 was $37.8 million, compared to $40.7 million for first quarter 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/0001193125-23-140078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.